Literature DB >> 12688374

Structure of cholecystokinin receptor binding sites and mechanism of activation/inactivation by agonists/antagonists.

Daniel Fourmy1, Chantal Escrieut, Elodie Archer, Céline Galès, Véronique Gigoux, Bernard Maigret, Luis Moroder, Sandrine Silvente-Poirot, Jean Martinez, Jean-Alain Fehrentz, Lucien Pradayrol.   

Abstract

Delineation of CCK receptor binding sites is a prerequisite for the understanding of the molecular basis for ligand recognition, partial agonism, ligand-induced traffiking of receptor signalling. In the current paper, we illustrate how, in the past 5 years, studies from our laboratory and others have provided new data on the molecular basis of the pharmacology and functioning of CCK1 and CCK2 receptors. Available data on CCK1 and CCK2R binding sites indicate that 1) homologous regions of the two receptors are involved in the binding site of CCK, however, positioning of CCK slightly differs; 2) binding sites of non-peptide agonists/antagonist are buried in the pocket formed by transmembrane helices and overlap that of CCK and 3) residues of the binding sites as well as of conserved motifs such as E/DRY, NPXXY are crucial for receptor activation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12688374     DOI: 10.1034/j.1600-0773.2002.910608.x

Source DB:  PubMed          Journal:  Pharmacol Toxicol        ISSN: 0901-9928


  9 in total

1.  Cell-specific targeting by heterobivalent ligands.

Authors:  Jatinder S Josan; Heather L Handl; Rajesh Sankaranarayanan; Liping Xu; Ronald M Lynch; Josef Vagner; Eugene A Mash; Victor J Hruby; Robert J Gillies
Journal:  Bioconjug Chem       Date:  2011-06-16       Impact factor: 4.774

2.  Probing a model of a GPCR/ligand complex in an explicit membrane environment: the human cholecystokinin-1 receptor.

Authors:  Jérôme Hénin; Bernard Maigret; Mounir Tarek; Chantal Escrieut; Daniel Fourmy; Christophe Chipot
Journal:  Biophys J       Date:  2005-12-02       Impact factor: 4.033

Review 3.  Challenges to the therapeutic pipeline for irritable bowel syndrome: end points and regulatory hurdles.

Authors:  Michael Camilleri; Lin Chang
Journal:  Gastroenterology       Date:  2008-10-09       Impact factor: 22.682

Review 4.  Irritable bowel syndrome: recent and novel therapeutic approaches.

Authors:  Viola Andresen; Michael Camilleri
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 5.  Current and novel therapeutic options for irritable bowel syndrome management.

Authors:  M Camilleri; V Andresen
Journal:  Dig Liver Dis       Date:  2009-08-08       Impact factor: 4.088

6.  Solid-Phase Synthesis of Heterobivalent Ligands Targeted to Melanocortin and Cholecystokinin Receptors.

Authors:  Jatinder S Josan; Josef Vagner; Heather L Handl; Rajesh Sankaranarayanan; Robert J Gillies; Victor J Hruby
Journal:  Int J Pept Res Ther       Date:  2008-12       Impact factor: 1.931

7.  Signaling properties and pharmacological analysis of two sulfakinin receptors from the red flour beetle, Tribolium castaneum.

Authors:  Sven Zels; Heleen Verlinden; Senne Dillen; Rut Vleugels; Ronald J Nachman; Jozef Vanden Broeck
Journal:  PLoS One       Date:  2014-04-09       Impact factor: 3.240

8.  Synthesis and Pharmacological Characterization of Visabron, a Backbone Cyclic Peptide Dual Antagonist of α4β1 (VLA-4)/α9β1 Integrin for Therapy of Multiple Sclerosis.

Authors:  Chaim Gilon; Michal Klazas; Adi Lahiani; Adi Schumacher-Klinger; Shira Merzbach; Johnny N Naoum; Haim Ovadia; Limor Rubin; Susan Cornell-Kennon; Erik M Schaefer; Jehoshua Katzhendler; Cezary Marcinkiewicz; Amnon Hoffman; Philip Lazarovici
Journal:  JACS Au       Date:  2021-11-24

9.  Cholecystokinin receptors in Atlantic salmon: molecular cloning, gene expression, and structural basis.

Authors:  Raja M Rathore; Anna R Angotzi; Ann-Elise O Jordal; Ivar Rønnestad
Journal:  Physiol Rep       Date:  2013-10-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.